What Do Washington Adverse Event Reports Reveal About Tysabri and PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Science to Targeted Risk Communication

If you or a loved one is taking Tysabri and concerned about progressive multifocal leukoencephalopathy (PML), you may wonder what adverse event reports from Washington state reveal. These reports offer real-world data, but they come with important limitations. The tradition of gathering and analyzing such reports has long helped clinicians and regulators track drug safety, yet interpreting them requires careful attention to what they can and cannot tell us. This page reviews the available Washington adverse event data on Tysabri-associated PML, focusing on the factual boundaries of these reports.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug carries a boxed warning stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by reactivation of the John Cunningham virus (JCV) in the central nervous system, leading to demyelination and progressive neurological decline. The clinical presentation of PML typically includes subacute onset of focal neurological deficits, such as weakness, gait disturbance, visual field defects, cognitive impairment, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The disease course is often rapid, with severe disability or death occurring within months of symptom onset. The boxed warning emphasizes that healthcare professionals should monitor patients on Tysabri for any new sign or symptom suggestive of PML and withhold dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of Action and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their adhesion to vascular cell adhesion molecule-1 on endothelial cells. This blockade inhibits lymphocyte migration across the blood-brain barrier, reducing inflammatory activity in the central nervous system. However, this immunosuppressive effect also impairs immune surveillance against JCV, allowing the virus to reactivate and proliferate unchecked in the brain. The boxed warning identifies three key risk factors for PML development: the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are seropositive for anti-JCV antibodies, have received Tysabri for more than two years, or have previously taken immunosuppressive medications face the highest risk. The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning is prominently displayed in the prescribing information, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, patients must read the Medication Guide, understand the risks, and sign a Patient Enrollment Form. Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers adequately communicated the risk of PML to patients, particularly regarding the cumulative nature of risk over time and the implications of prior immunosuppressant use.

Statute of Limitations for Tysabri Claims in Washington

For patients in Washington who developed PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Washington, the statute of limitations for personal injury claims generally is three years from the date the injury was discovered or should have been discovered with reasonable diligence. For PML, the timeline between exposure to Tysabri and documented harm can vary. The boxed warning notes that PML risk increases with duration of therapy, and cases have been reported after varying treatment lengths. The prescribing information also notes that herpes encephalitis and meningitis cases have occurred with Tysabri, with onset ranging from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the importance of prompt legal evaluation to determine when the injury was discovered and whether the claim falls within the statutory window. Adverse event data from the FDA FAERS database show that Tysabri is associated with a range of neurological and systemic symptoms, including fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically confirm PML, they highlight the drug's potential to cause significant neurological adverse effects. For patients who develop PML, the consequences are severe, often leading to permanent disability or death. The boxed warning explicitly states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, Tysabri carries a well-documented risk of PML, with established risk factors and a mechanistic basis involving impaired immune surveillance. The drug's labeling includes a boxed warning and a restricted distribution program, but questions about the adequacy of risk communication may persist. For affected patients in Washington, the statute of limitations for legal action is typically three years from discovery of the injury, and the variable latency between Tysabri exposure and PML onset necessitates timely legal consultation. Evidence-based evaluation of each case should consider the patient's risk factors, duration of therapy, and the timing of symptom onset relative to treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. Because PML can develop months to years after starting Tysabri, it is crucial to consult an attorney promptly to determine if your claim falls within this window.

What are the key risk factors for developing PML while on Tysabri?

The boxed warning for Tysabri identifies three key risk factors: the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressant medications. Patients with these factors are at highest risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed and what are its symptoms?

PML is diagnosed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. Symptoms include subacute onset of focal neurological deficits such as weakness, gait disturbance, visual field defects, cognitive impairment, and speech difficulties. The disease often progresses rapidly to severe disability or death.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.